Study on clinical rational use of fleroxacin based on Monte Carlo method
Chu Qixing
Abstract：Objective To optimize clinical optimal dosing regimen of fleroxacinby the study of pharmacoKinetic/pharmacody-namics( PK/PK)model. Methods The minimum inhibitory concentration( MIC)of fleroxacin was determined and AUC0~24/MIC after administration was calculated by MIC and single-dose pharmacoKinetics. The pharmacodynamic relationship between different doses was confirmed by Monte Carlo simulation to provide the basis for clinical treatment. Results AUC0~24 of fleroxa-cin with low,medium and high doses were 5. 3、6. 5、7. 4 μg/ml respectively,AUC0~∞ were 7. 3、8. 6、9. 5 μg/ml,T1/2 were 18. 6、17. 5、20. 2 h,and the performance was linear pharmacoKinetic characteristics. Sensitivities of fleroxacin towards different pathogenic bacterias and different strains of the same species were ﹤0. 01~1. 00 of salmonella to 0. 05~10. 00 of pseudomonas aeruginosa. The Monte Carlo simulation based on pharmacoKinetic/pharmacodynamics showed that pharmacodynamic cumulative fraction of response of fleroxacin with the dose of 300 mg towards serratia marcescens,escherichia coli,acinetobacter and methi-cillin-sensitive staphylococcus aureus could achieve more than 90%. The pharmacodynamic cumulative fraction of response of fleroxacin with the dose of 200 mg towards mora catarrhal bacteria and salmonella could achieve more than 90%. The pharmaco-dynamic cumulative fraction of response of fleroxacin with the dose of 400 mg towards other strains could achieve more than 90%. Conclusion Kifferent doses of fleroxacin were needed for different bacterial infection. An increasing dosage,such as 400 mg, could achieve a satisfactory clinical curative effect for infections caused by methicillin-resistant staphylococcus aureus.
Keywords：fleroxacinMonte Carlo simulationrational drug use
Publication Date：2015-01-01
Online Publishing Date：2026-09-12(First online date of this platform, not the publication date of the document)
Pages：4( 6-9 )